Morgan Stanley has a “buy” rating on the stock. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $16.84, according to the report.
More articles on gastroenterology:
Check-Cap IPO unites to trade separately from March 18 onwards
Akron General Partners Physician Group adds Dr. Jeffery Neher
Actavis completes $70.5B Allergan acquisition
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
